Wang Jiali, Wang Chong, Wang Qiao, Zhang Zhuohao, Wang Hui, Wang Shengyi, Chi Zhangcai, Shang Luoran, Wang Wuqing, Shu Yilai
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai200031, P. R. China.
NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai200031, P. R. China.
ACS Appl Mater Interfaces. 2022 Oct 19;14(41):46212-46223. doi: 10.1021/acsami.2c11647. Epub 2022 Oct 7.
Local drug delivery has become an effective method for disease therapy in fine organs including ears, eyes, and noses. However, the multiple anatomical and physiological barriers, unique clearance pathways, and sensitive perceptions characterizing these organs have led to suboptimal drug delivery efficiency. Here, we developed dexamethasone sodium phosphate-encapsulated gelatin methacryloyl (Dexsp@GelMA) microgel particles, with finely tunable size through well-designed microfluidics, as otic drug delivery vehicles for hearing loss therapy. The release kinetics, encapsulation efficiency, drug loading efficiency, and cytotoxicity of the GelMA microgels with different degrees of methacryloyl substitution were comprehensively studied to optimize the microgel formulation. Compared to bulk hydrogels, Dexsp@GelMA microgels of certain sizes hardly cause air-conducted hearing loss . Besides, strong adhesion of the microgels on the round window membrane was demonstrated. Moreover, the Dexsp@GelMA microgels, intratympanic administration, could ameliorate acoustic noise-induced hearing loss and attenuate hair cell loss and synaptic ribbons damage more effectively than Dexsp alone. Our results strongly support the adhesive and intricate microfluidic-derived GelMA microgels as ideal intratympanic delivery vehicles for inner ear disease therapies, which provides new inspiration for microfluidics in drug delivery to the fine organs.
局部给药已成为在包括耳、眼和鼻等精细器官中进行疾病治疗的有效方法。然而,这些器官所具有的多种解剖学和生理学屏障、独特的清除途径以及敏感的感知功能导致药物递送效率欠佳。在此,我们通过精心设计的微流控技术开发出了尺寸可精细调控的载有地塞米松磷酸钠的甲基丙烯酰化明胶(Dexsp@GelMA)微凝胶颗粒,将其作为用于听力损失治疗的耳部药物递送载体。全面研究了不同甲基丙烯酰取代度的GelMA微凝胶的释放动力学、包封率、载药率和细胞毒性,以优化微凝胶配方。与块状水凝胶相比,特定尺寸的Dexsp@GelMA微凝胶几乎不会导致气导性听力损失。此外,还证明了微凝胶在圆窗膜上具有很强的附着力。而且,经鼓室内给药的Dexsp@GelMA微凝胶比单独使用地塞米松磷酸钠更能有效改善噪声诱发的听力损失,并减轻毛细胞损失和突触带损伤。我们的研究结果有力地支持了具有粘附性且由微流控技术制备的GelMA微凝胶作为内耳疾病治疗理想的鼓室内递送载体,这为微流控技术在向精细器官给药方面提供了新的灵感。